Drug Profile


Alternative Names: Equa; Galvus; Jalra; LAF 237; LAF 237A; NVP LAF 237; NVP LAF 237A; Xiliarx

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; Samsung Medical Center; University of Sao Paulo
  • Class Antihyperglycaemics; Cycloparaffins; Nitriles; Polycyclic bridged compounds; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 01 Aug 2017 Novartis completes a phase II trial in Type-2 diabetes mellitus (Combination therapy) in South Korea (PO) (NCT01404676)
  • 29 May 2017 Discontinued - Phase-II/III for Type-2 diabetes mellitus (Treatment-naive) in India (PO)
  • 29 May 2017 Discontinued - Phase-II/III for Type-2 diabetes mellitus (Treatment-naive) in Malaysia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top